Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN Study

Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatmentПодробнее

Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUINПодробнее

Pirtobrutinib in R/R FL: results from the BRUIN studyПодробнее

Sequencing of BTK inhibitors in CLLПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее

Advances in non-covalent BTK inhibitors for CLL: BRUIN study updateПодробнее

Pirtobrutinib for Chronic Lymphocytic Leukemia (CLL) Patients - Dr. Nirav Shah ASH 2022Подробнее

Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trialПодробнее

Current state of the field: non-covalent BTK inhibitors for CLLПодробнее

Ongoing trials investigating the efficacy of pirtobrutinib in CLLПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее

Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN studyПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

BRUIN MCL-321: pirtobrutinib vs investigator choice of BTK inhibitor in BTK inhibitor-naive MCLПодробнее

Novel therapies in chronic lymphocytic leukemia: An update.Подробнее